Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab Dose Comparison in Recurrent or Metastatic Head and Neck Cancer
NCT00661427Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 2007
- Primary completion
- Aug 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of KL-140 in head and neck squamous cell carcinoma (HNSCC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Overall Objective Response. Started Nov 2007; status: completed.
02
Drugs
KL-140
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00661427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00661427.